AMANDA FREESE: Open Payments
NPI 1760994925 · OLNEY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,346 in 32 payments from 17 companies in 2025. Trend: 2023 $308 · 2024 $664 · 2025 $1,346
Food & beverage: $1,346
| Company | Payments | Amount |
|---|---|---|
| AOP Health US, LLC | 1 | $695 |
| PFIZER INC. | 5 | $115 |
| Actelion Pharmaceuticals US, Inc. | 4 | $104 |
| Novartis Pharmaceuticals Corporation | 5 | $87 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Kestra Medical Technology Services, Inc. | 2 | $38 |
| Boston Scientific Corporation | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| Novo Nordisk Inc | 1 | $35 |
| ARGENX US, INC. | 1 | $28 |
Products named: Rapiblyk, VYNDAQEL, LEQVIO, OPSUMIT, NEXLETOL, Assure WCD, CDS - MCT/CEM Monitoring, Wegovy.
Industry payments across MD — which companies pay providers there.
